EMERGENT RESISTANCE TO ANTIRETROVIRAL AGENTS USED IN OPTIMIZED BACKGROUND THERAPY WITH FOSTEMSAVIR: WEEK 96 RESULTS OF THE PHASE 3 BRIGHTE STUDY IN HEAVILY TREATMENT-EXPERIENCED ADULTS LIVING WITH MULTIDRUG-RESISTANT HIV-1
EACS 2021 Oct 27-30
Margaret Gartland,1 Amy Pierce,1 Louise Garside,2 Marcia Wang,3 Fangfang Du,3 Shiven Chabria,4
Mark Krystal,4 Andrew Clark,5 Peter Ackerman,4 Max Lataillade4
